Silence Therapeutics plc (NASDAQ: SLNCF)

Silence Therapeutics plc, a biotechnology company, is dedicated to discovering and developing innovative molecules that incorporate short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes believed to be involved in the pathology of diseases with significant unmet medical needs. The company's siRNA molecules harness the body's natural mechanism of RNA interference (RNAi) by specifically binding to and degrading messenger RNA (mRNA) molecules that encode specific disease-associated proteins in a cell.

Silence Therapeutics' main business activities revolve around its liver-targeting mRNAi GOLDâ„¢ platform. This platform is a comprehensive toolbox that consists of proprietary chemical modifications, liver cell targeting technology, and a target selection and screening process. The platform is designed to enable the development of siRNA molecules that can be delivered to the liver, where they can specifically bind to and degrade target mRNAs, thereby reducing the production and activity of disease-associated proteins.

The company's primary products are siRNA molecules, including zerlasiran (SLN360) and divesiran (SLN124). Zerlasiran is designed to treat cardiovascular disease by lowering the body's production of apolipoprotein(a), a key component of lipoprotein(a), which has been associated with an increased risk of cardiovascular events. Divesiran, on the other hand, is designed to inhibit the expression of TMPRSS6, a gene that regulates the production of hepcidin, a peptide hormone that is the master regulator of systemic iron balance, thereby addressing hematology disorders.

Silence Therapeutics' siRNA product candidates are administered by subcutaneous injection and have the potential to reduce disease-associated protein production and activity. The company's pipeline is centered around its liver-targeting mRNAi GOLDâ„¢ platform and consists of a diversified set of therapeutic areas, including cardiovascular disease, hematology, and rare diseases.

The company's position within the industry is strong, with a proprietary mRNAi GOLDâ„¢ platform that has been validated through ongoing research and development collaborations with leading pharmaceutical companies. These collaborations have not only validated the platform but also established the company's credibility and position in the industry. Silence Therapeutics has also established partnerships with third-party collaborators to develop and commercialize its siRNA product candidates, further strengthening its position.

The company's customers include leading pharmaceutical companies, such as AstraZeneca, Mallinckrodt, and Hansoh. These companies have partnered with Silence Therapeutics to develop and commercialize its siRNA product candidates, indicating the company's product candidates' potential and the trust they have garnered within the industry. The company's siRNA product candidates have also been tested in clinical trials, with positive results reported in several studies, further attesting to their efficacy and potential.